- Home
- TMO vs NVO Comparison
TMO vs NVO Comparison
Compare TMO & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMO | NVO |
|---|---|---|
| Founded | 1956 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.8B | 166.1B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | TMO | NVO |
|---|---|---|
| Price | $473.12 | $45.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 18 | 11 |
| Target Price | ★ $636.00 | $51.00 |
| AVG Volume (30 Days) | 1.9M | ★ 14.3M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | 0.40% | ★ 3.19% |
| EPS Growth | ★ 7.32 | N/A |
| EPS | ★ 4.43 | N/A |
| Revenue | ★ $20,918,000,000.00 | N/A |
| Revenue This Year | $6.55 | N/A |
| Revenue Next Year | $5.11 | $3.70 |
| P/E Ratio | $105.34 | ★ $13.60 |
| Revenue Growth | ★ 14.47 | N/A |
| 52 Week Low | $385.46 | $35.12 |
| 52 Week High | $643.99 | $81.44 |
Technical Indicators
Market Signals| Indicator | TMO | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.41 | 73.40 |
| Support Level | $454.22 | $45.43 |
| Resistance Level | $497.64 | $50.30 |
| Average True Range (ATR) | 13.24 | 1.07 |
| MACD | -2.90 | 0.69 |
| Stochastic Oscillator | 19.96 | 83.37 |
Price Performance
Historical ComparisonAbout TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.